Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy
T cells are one of the most important effector cells in cancer immunotherapy. Various T cell-dependent bispecific antibody (TDB) drugs that engage T cells for targeted cancer cell lysis are being developed. Here, we describe supra-molecular T-cell redirecting antibody fragment-anchored liposomes (TR...
Saved in:
Main Authors: | Fang Xie (Author), Luchen Zhang (Author), Sanyuan Shi (Author), Anjie Zheng (Author), Jiaxing Di (Author), Shanshan Jin (Author), Xuguang Miao (Author), Fenglan Wu (Author), Xiaolong Chen (Author), Yanhong Zhang (Author), Xiaohui Wei (Author), Yuhong Xu (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy
by: Yang Yang, et al.
Published: (2023) -
Danzon re-nominated as WHO Regional Director for Europe
Published: (2004) -
Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1
by: Jize Liu, et al.
Published: (2023) -
Immune cell landscape and immunotherapy of medulloblastoma
by: Jin Zhang, et al.
Published: (2021) -
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
by: Zili Gu, et al.
Published: (2020)